Use of Altabax Ointment (Retapamulin 1%) BID for 7 Days in Treatment of Secondary Infection With Staphylococcus Aureus (MRSA and MSSA) and Streptococcus Pyogenes in Atopic Dermatitis Patients - Open Label Pilot Study
Sponsor study identifier
interventional
29
1 country
1
Study Start
February 2010
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
January 2012
Actual (reported)Study Completion
January 2012
Actual (reported)Skin infections may complicate the treatment of atopic dermatitis.The use of topical ointments has become very important to avoid the use of oral antibiotics. There is little supporting literature regarding the use of topical antibiotics in secondarily infected atopic dermatitis. This study will investigate the safety and effectiveness of Altabax ointment use in treating secondarily infected atopic dermatitis caused by Staphylococcus aureus and Streptococcus pyogenes.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 2012
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 2010
Date type not reportedThis date has not been verified as actual or estimated.
February 8, 2010
Actual (reported)February 9, 2010
Actual (reported)January 2012
Actual (reported)January 2012
Actual (reported)July 4, 2013
Actual (reported)Bacteriological Culture
All participants were cultured for S.aureus (MRSA), S.aureus (MSSA) and S. pyogenes at Baseline. If positive at Baseline then they were cultured again at Day 7.
Day 1 and Day 7
Skin Infection Rating Scale (SIRS)
Day 1 and Day 7
Investigator Assessment of Clinical Cure
Day 7
Local Tolerability
Day 7
Apply a thin layer of Retapamulin 1% to the affected area twice daily. The treated area may be covered with a sterile bandage or gauze dressing if desired.
DermResearch, PLLC
Louisville, Kentucky, 40217, United States
small number of subjects/short duration of study treatment
Leon H. Kircik, M.D.
DermResearch, PLLC
29 participants (actual enrollment reported by the registry).
First Submitted
February 8, 2010
First Posted
February 9, 2010
Study Start
February 2010
Date type not reportedThis date has not been verified as actual or estimated.
Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Low-Potency Corticosteroids Versus Low-Potency Corticosteroid Mono-therapy
Contact the study team to confirm eligibility.
Primary Completion
January 2012
Actual (reported)Study Completion
January 2012
Actual (reported)Last Updated
September 22, 2016
Results First Posted
July 4, 2013
Record last verified: 2013-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: